Stephen V Liu: Retrospective report on EGFR mutant NSCLC transformed to SCLC

Stephen V Liu shared a post on X:

“Retrospective report in European Journal of Cancer on EGFR mutant NSCLC transformed to SCLC. Post transformation, 93% were DLL3 positive. Are BiTEs like tarlatamab viable options here? No clear current standard (chemo, chemo + TKI, chemo + IO).”

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Authors: Felix Carl Saalfeld, et al.

Tejas Patil, Thoracic oncologist CU Cancer Center, commented on Stephen V Liu’s post, adding:

“Very provocative finding for patients with EGFR NSCLC with SCLC transformation.

My immediate next question is what is the efficacy of DLL3 T cell bispecifics and TKI among cases where DLL3 expression is enriched?”

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.